Chemo-radiotherapy in nasopharyngeal carcinoma at Ramathibodi Hospital, Bangkok.
Combined chemotherapy (Cis-platinum and 5 FU) and radiation therapy were given to 11 patients with stage IV (except 1) nasopharyngeal carcinoma. None had distant metastasis. Mean duration of follow-up was 16.2 months. Objective response (CR+PR) at the primary lesion were 10 out of 11 (90.9%), while CR was 7 out of 11 (63.6%). CR+PR at the regional node were 10 out of 10 (100%), while CR was 9 out of 10 (90%). There has been no recurrence so far. One patient died of hepatocellular carcinoma. Side effects, mainly from radiation therapy, were clinically acceptable. One had transient cervical myelitis, which improved after medical treatment. There was no significant myelosuppression.
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002277:Carcinoma / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D004854:Herpesvirus 4, Human / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D009367:Neoplasm Staging; D013785:Thailand
D000914:Antibodies, Viral